ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).

被引：0
|
作者：
Lonial, Sagar
Richardson, Paul Gerard Guy
Moreau, Philippe
Orlowski, Robert Z.
San-Miguel, Jesus F.
Dimopoulos, Meletios A.
Palumbo, Antonio Pierangelo
Facon, Thierry
Vij, Ravi
White, Darrell
Reece, Donna Ellen
Singhal, Anil
Kroog, Glenn Scott
Kopit, Justin
Anderson, Kenneth Carl
机构：
[1] Multiple Myeloma Res Consortium, Norwalk, CT USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hosp, Nantes, France
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Hosp Univ Salamanca, Salamanca, Spain
[7] Hellen Cooperat Oncol Grp, Athens, Greece
[8] Univ Turin, Turin, Italy
[9] Hop Claude Huriez, Lille, France
[10] Washington Univ, Sch Med, St Louis, MO USA
[11] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[12] Princess Margaret Hosp, Program Multiple Myeloma, Toronto, ON M4X 1K9, Canada
[13] Abbott Biotherapeut, Redwood City, CA USA
[14] Bristol Myers Squibb Co, Global Clin Res Oncol, Princeton, NJ USA
[15] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8112
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    White, Darrell
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Moreau, Philippe
    Mateos, Maria-Victoria
    Magen-Nativ, Hila
    Belch, Andrew
    Reece, Donna Ellen
    Beksac, Meral
    Taniwaki, Masafumi
    Roellig, Christoph
    Singhal, Anil K.
    Katz, Jessica
    Bleickardt, Eric W.
    Poulart, Valerie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Lonial, S.
    Palumbo, A.
    White, D.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Moreau, P.
    Mateos, M. -V.
    Magen, H.
    Belch, A.
    Reece, D.
    Beksac, M.
    Spencer, A.
    Oakervee, H.
    Taniwaki, M.
    Roellig, C.
    Wu, K. L.
    Singhal, A.
    San Miguel, J.
    Matsumoto, M.
    Katz, J.
    Bleickardt, E.
    Poulart, V.
    Richardson, P.
    HAEMATOLOGICA, 2015, 100 : 173 - 173
  • [3] A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).
    Jakubowiak, Andrzej J.
    White, Darrell
    Moreau, Philippe
    Facon, Thierry
    Vij, Ravi
    Kroog, Glenn Scott
    Kopit, Justin
    Singhal, Anil
    Palumbo, Antonio Pierangelo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).
    Dimopoulos, Meletios A.
    Facon, Thierry
    Richardson, Paul Gerard Guy
    Orlowski, Robert Z.
    San-Miguel, Jesus F.
    Lonial, Sagar
    Anderson, Kenneth Carl
    Moreau, Philippe
    Reece, Donna Ellen
    Singhal, Anil
    Shazer, Ronald L.
    Kopit, Justin
    Palumbo, Antonio Pierangelo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] ELOQUENT-2: Extended safety and efficacy follow-up of the phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M-V
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A.
    Richardson, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 6 - 7
  • [6] A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Jakubowiak, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Tsao, L. C.
    Lynch, M.
    Bleickardt, E.
    Jou, Y. M.
    Palumbo, A.
    HAEMATOLOGICA, 2015, 100 : 2 - 2
  • [7] Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
    Dimopoulos, Meletios A.
    Weisel, Katja
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth C.
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Ganetsky, Alex
    Jou, Ying-Ming
    McKiver, Mihaela Popa
    Singhal, Anil K.
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E15 - E16
  • [8] Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-3-Year Safety and Efficacy Follow-up
    Dimopoulos, Meletios A.
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Palumbo, Antonio
    San Miguel, Jesus
    Shpilberg, Ofer
    Anderson, Kenneth C.
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen-Nativ, Hila
    Mateos, Maria-Victoria
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Bleickhardt, Eric
    Poulart, Valerie
    Katz, Jessica
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [9] Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN plus DEX) vs LEN plus DEX in relapsed/refractory multiple myeloma (R/R MM).
    Alsaid, Nimer
    McBride, Ali
    Agarwal, Amit Balkrishna
    Mutairi, Abdulaali
    Anwer, Faiz
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
    Moreau, P.
    Palumbo, A. P.
    Stewart, A. K.
    Rajkumar, V.
    Jakubowiak, A. J.
    Halka, K.
    Goranov, S.
    Bumbea, H.
    Pendergrass, K. B.
    Lupu, A.
    Dimopoulos, A.
    Rocafiguera, A. O.
    Gandhi, J. G.
    Mihaylov, G.
    Masszi, T.
    Matous, J.
    Fonseca, G.
    Bryce, R.
    Siegel, D. S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345